Avecia adds formulation studies to its portfolio of services

Avecia Biologics, a privately-owned biotech group of companies, has created a new formulation development capability based at its Tees Valley, UK laboratories to improve its service offering to customers.

Avecia Biologics, a privately-owned biotech group of companies, has created a new formulation development capability based at its Tees Valley, UK laboratories to improve its service offering to customers.

Using Avecia's 10-year knowledge and experience of biologics development work, the new unit aims to bring together biochemical, bioanalytical and biophysical techniques.

Formulation studies are fundamental to ensuring a stable and effective product. The complex nature of most biological molecules including properties such as aggregation and stability makes the development and implementation of a structured and carefully designed programme essential.

"This must be done early in the development life of a product to gain maximum benefit from clinical studies and avoid late-stage changes in formulation or a product that fails to deliver its expected effect. Such failures can fundamentally undermine the success of early-stage biotechnology companies

The company says the new capability will offer real time, cost and technical advantages for its customers.

The process development and analytical team will build knowledge of the behaviour of the target biologic. And by incorporating formulation studies directly into the Avecia process development programme, aligning both in parallel in a highly iterative process, the overall development timeline through to the clinic can be minimised.

Companies